LoginRegister

    USFDA nod for Zydus Pharmaceuticals OCD treatment drug

    Written by Ruby Khatun Khatun   |  
    USFDA nod for Zydus Pharmaceuticals OCD treatment drug

    New Delhi: Zydus Pharmaceuticals (USA) Inc has received final approval from the US health regulator to market Clomipramine Hydrochloride capsules, used to treat obsessive compulsive disorder (OCD).


    The company has received final approval from the US Food and Drug Administration (USFDA) to market the drug in the strength of 25 mg, 50 mg, and 75 mg, Zydus Cadila said in a BSE filing.


    The company will produce the drug at the group's formulations manufacturing facility at SEZ, Ahmedabad.


    Clomipramine hydrochloride capsule is used to treat obsessive compulsive disorder, which is characterised by uncontrollable, re-occurring thoughts and behaviours.


    The company has more than 180 approvals and so far filed over 310 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.


    Zydus Pharmaceuticals Inc is a wholly-owned subsidiary of Cadila Healthcare Ltd.

    abbreviated new drug applicationsCadila HealthcareClomipramine HydrochlorideClomipramine Hydrochloride capsulesdrugmarketobsessive compulsive disorderOCDtreatmentUS Food and Drug AdministrationUSFDAzydusZydus CadilaZydus PharmaceuticalsZydus Pharmaceuticals USA Inc
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X